Skip to main content
SpringerLink
Log in

Prostatakarzinom

Aktuelles und praxisrelevantes in der Urologie 2011

Prostate cancer

Current and practice-relevant news from urology in 2011

  • Übersichten
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Beim Prostatakarzinom wurde die Wirkung der 5α-Reduktaseinhibitoren umfangreich untersucht. Dabei wurde durch Finasterid als auch durch Dutasterid eine Reduktion des Risikos, ein Prostatakarzinom zu erlangen, festgestellt – hierbei wurden jedoch insbesondere Hochrisikokarzinome nicht reduziert und möglicherweise scheinbar sogar vermehrt. Dies wird in der S3-Leitlinie für das Prostatakarzinom entsprechend dargestellt. Neue Daten zur Früherkennung zeigen, dass die prostatakarzinomspezifische Sterblichkeit bei längerer Nachbeobachtung durch Screening effektiver reduziert werden kann, als es die initial publizierten Daten der ERSPC-Studie (Europäische Screeningstudie für das Prostatakarzinom) zeigten. Die aktive Überwachung gewinnt in der Therapie des frühen Prostatakarzinoms zunehmend an Bedeutung. Weitere neue Arbeiten zeigen ein gutes Ergebnis für operierte Patienten mit Hochrisikoprostatakarzinom. Für das metastasierte Prostatakarzinom stehen sowohl neue immuntherapeutische, chemotherapeutische und hormontherapeutische Optionen zur Verfügung bzw. sind kurz vor der Zulassung.

Abstract

The effect of 5α reductase inhibitors in prostate cancer has been extensively investigated. The studies determined that finasteride and also dutasteride reduced the risk of prostate cancer; however, particularly high-grade cancer was not reduced and may possibly even have been increased. This is appropriately reflected in the S3 guideline on prostate cancer. New data on early recognition show that after longer term observation prostate cancer-specific mortality can be more effectively reduced by screening than was initially shown by the original data from the ERSPC study. Active surveillance is becoming more important for the therapy of early prostate cancer. Other new publications have shown good results for patients who underwent surgery for high risk prostate cancer. For metastasized prostate cancer new immunotherapeutic, chemotherapeutic and hormonal options are now available or will soon be approved.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Thompson IM, Chi C, Ankerst DP et al (2006) Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98(16):1128–1133

    Article  PubMed  CAS  Google Scholar 

  2. Andriole GL, Bostwick DG, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192–1202

    Article  PubMed  CAS  Google Scholar 

  3. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328

    Article  PubMed  Google Scholar 

  4. Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11(8):725–732

    Article  PubMed  Google Scholar 

  5. Bergh RC van den, Roemeling S, Roobol MJ et al (2009) Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55(1):1–8

    Article  PubMed  Google Scholar 

  6. Gesundheitsministerium (2010) Gesundheitsberichterstattung des Bundes. Gesundheitsministerium, Berlin, http: / / www.gbe-bund.de / 

  7. Droz JP, Balducci L, Bolla M et al (2010) Management of prostate cancer in older men:recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 106(4):462–469

    Article  PubMed  Google Scholar 

  8. Bill-Axelson A, Holmberg L, Ruutu M et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708–1717

    Article  PubMed  CAS  Google Scholar 

  9. Abdollah F, Sun M, Montorsi F et al (2011) A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients. Eur Urol 59(1):88–95

    Article  PubMed  Google Scholar 

  10. Cooperberg MR, Vickers AJ, Broering JM et al (2010) Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116(22):5226–5234

    Article  PubMed  Google Scholar 

  11. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422

    Article  PubMed  CAS  Google Scholar 

  12. Bono JS de, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154

    Article  PubMed  Google Scholar 

  13. Bono JS de, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Amgen GmbH, AstraZeneca GmbH, Takeda Pharma GmbH, Ferring Arzneimittel GmbH, Glaxo Smith Kline GmbH&Co. KG, Novartis Pharma GmbH, Pfizer Pharma GmbH.

Author information

Authors and Affiliations

  1. Universitätsklinikum Dresden, Fetscherstraße 74, Haus 8, 01307, Dresden, Deutschland

    M. Wirth & S. Zastrow

Authors
  1. M. Wirth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Zastrow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Wirth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wirth, M., Zastrow, S. Prostatakarzinom. Urologe 50 (Suppl 1), 173 (2011). https://doi.org/10.1007/s00120-011-2680-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s00120-011-2680-x

Schlüsselwörter

Keywords

Search

Navigation